Activin and Inhibin

GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pK i of 8.9.In VivoCocaine and GSK598809 each increases peak mean arterial blood pressure. Least square mean differences are significant for both doses of cocaine

GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pK i of 8.9.In VivoCocaine and GSK598809 each increases peak mean arterial blood pressure. Least square mean differences are significant for both doses of cocaine

GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pK i of 8.9.In VivoCocaine and GSK598809 each increases peak mean arterial blood pressure. Least square mean differences are significant for both doses of cocaine

GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pK i of 8.9.In VivoCocaine and GSK598809 each increases peak mean arterial blood pressure. Least square mean differences are significant for both doses of cocaine

GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist, with a pK i of 8.9.In VivoCocaine and GSK598809 each increases peak mean arterial blood pressure. Least square mean differences are significant for both doses of cocaine

GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC 50 of 7.4.In VitroGSK726701A has high selectivity (&gt:100-fold) against a set of other prostaglandin receptors (EP1-3 , DP1 , FP, IP, TP) and no significant activity

GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC 50 of 7.4.In VitroGSK726701A has high selectivity (&gt:100-fold) against a set of other prostaglandin receptors (EP1-3 , DP1 , FP, IP, TP) and no significant activity

GSK726701A is a novel prostaglandin E2 receptor 4 (EP4) partial agonist with a pEC 50 of 7.4.In VitroGSK726701A has high selectivity (&gt:100-fold) against a set of other prostaglandin receptors (EP1-3 , DP1 , FP, IP, TP) and no significant activity

GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC 50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the

GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC 50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the

GSK761 is a selective inhibitor of speckled 140 kDa (SP140) with an IC 50 value of 77.79 nM. GSK761 reduces monocyte-to-inflammatory macrophage differentiation and lipopolysaccharide (LPS)-induced inflammatory activation. GSK761 induces the

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC 50 s of 75 nM ( BRD2 BD1 ), 41 nM ( BRD3 BD1 ), 41 nM ( BRD4 BD1 ), and 143 nM ( BRDT BD1 ), respectively. GSK778 phenocopies the effects of pan- BET